Actuate Therapeutics Amends S-1: 65M Shares at $0.64, Major Holders Lock Up for Two Years
ACTU is trading near its 52-week low of $0.438 (8.3% above the low) on elevated volume (3.0× avg).
Summary
Actuate Therapeutics amended its S-1 to sell 65 million shares at an assumed $0.6437 per share, with major shareholders Bios and Kairos agreeing to two-year lock-ups in exchange for warrants. The offering is highly dilutive but provides critical runway for the cash-strapped biotech.
Key Events · Financing and Capital Events · ACTU
-
Offering Reduced to 65M Shares
Pre-Effective Amendment No. 1 reduces the offering to 65,000,000 shares at an assumed price of $0.6437 per share, down from the originally registered $47.1 million. Gross proceeds would be approximately $41.8 million.
-
Major Holders Lock Up for Two Years
Bios Entities and Kairos Entities, owning ~50% of outstanding shares, agreed to two-year lock-ups in exchange for warrants to purchase 3,000,000 and 700,000 shares respectively at 150% of the offering price.
-
Massive Dilution for Existing Holders
Post-offering share count rises from 24,013,577 to 89,013,577 shares — a 270% increase. New investors face immediate dilution of $0.1937 per share at the assumed offering price.
-
Survival Financing Amid Delisting Risk
The company's cash runway ended in September 2026 and it faces a Nasdaq delisting notice with a January 11, 2027 compliance deadline. This offering is critical to fund operations.
Analysis · ACTU · Life Sciences
Actuate Therapeutics filed Pre-Effective Amendment No. 1 to its S-1, reducing the offering from the originally registered $47.1 million to 65 million shares at an assumed price of $0.6437 per share — roughly $41.8 million in gross proceeds. The amendment adds a critical new element: Bios Entities and Kairos Entities, which together own approximately 50% of outstanding shares, agreed to two-year lock-ups in exchange for warrants to purchase 3.7 million shares at 150% of the offering price. This is a survival financing for a company with a cash runway that ran out in September 2026 and an active Nasdaq delisting notice. The offering is highly dilutive — post-offering share count jumps from 24 million to 89 million shares, a 270% increase — but the insider lock-ups provide some signal of long-term commitment from the largest holders.
How filings like this one have moved
In the 30 days to Oct 14, 2026, 36.3% of the 974 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACTU was trading at $0.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.2M. The 52-week trading range was $0.44 to $8.30. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.